Anti-Human IL-6 – Biotin
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Goat Immunogen E. coli-Derived Recombinant Human Interleukin-6 (Accession # P05231) Formulation This biotinylated antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 50 µg of bovine serum albumin per µg of antibody with no calcium, magnesium, or preservatives present. State of Matter Lyophilized Storage and Handling The lyophilized, biotinylated antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for up to twelve months from date of receipt. The reconstituted biotin conjugate can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted conjugate, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2830601 Applications and Recommended Usage? Quality Tested by Leinco Western Blotting: To detect Human IL-6 this biotin conjugate can be used at a concentration of 0.1 - 0.2 µg/ml. This biotin conjugate should be used in conjunction with compatible second-step reagents such as PN:A106 and a chromogenic substrate such as PN:T343. The detection limit for Human IL-6 is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is PN:I-188. ELISA Sandwich Assay: This antibody can be used as the detection antibody in a sandwich ELISA at a concentration of approximately 0.1-0.4 µg/ml when used in conjunction with PN:I-633 as the capture antibody at 2 - 8 µg/ml and an optimal second step reagent such as PN:A106 for the detection of Human IL-6. Additional Applications Reported In Literature ? Immunocytochemistry: Suitable for use at concentration of 5-15 µg/mL. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Goat Anti-Human Interleukin-6 (IL-6) recognizes Human IL-6. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research. Background IL-6 is a pleotropic 26 kD protein that can act as both a pro-inflammatory cytokine and an anti-inflammatory myokine, a form of cytokine produced in muscle cells that participates in tissue regeneration and repair, maintenance of healthy bodily functioning, and homeostasis within the immune system. IL-6 plays a part in the immune, endocrine, nervous, and hematopoietic systems, in addition to bone metabolism, regulation of blood pressure and inflammation. Osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. Furthermore, IL-6 is an important mediator of fever and of the acute phase response which is the body's rapid attempt to restore homeostasis after tissue injury, infection, neoplastic growth, or immunological disturbance. In addition, IL-6 can be released into circulation in response to various stimuli including PAMPs (pathogen-associated molecular patterns) and cortisol, a hormone produced by the human body under psychologically stressful conditions. In its role as an anti-inflammatory myokine, IL-6 precedes the appearance of other cytokines in the circulation, is notably elevated with exercise, and is mediated by both its inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. IL-6 signals through a cell-surface type I cytokine receptor complex formed by the binding of IL-6 to IL-6R, forming a binary complex, which in turn combines with GP130 to transduce extracellular signaling by the activation STAT3. Hence, it is thought that blocking the interaction between IL-6 and GP130 may have therapeutic potential via the inhibition of the IL-6/GP130/STAT3 signaling pathway. Moreover, IL-6 initiates the inflammatory and auto-immune processes in many diseases such as diabetes, atherosclerosis, depression, Alzheimer's disease, rheumatoid arthritis, cancer, and various others. Thus, there is an interest in the therapeutic potential of anti-IL-6 mAbs. PubMed NCBI Gene Bank ID UniProt.org Research Area Other Molecules References & Citations1. Pederson, BK. et al. (2005) Exerc Sport Sci Rev 33: 114 2. Baier, M. et al. (1997) Proc Natl Acad Sci U S A. 94: 5273 Technical ProtocolsCertificate of Analysis |
Related Products
- -
- -
Prod No. | Description |
---|---|
I-633 | |
I-674 | |
I-1046 | |
I-1052 | |
I-1051 | |
I-213 | |
I-150 | |
I-165 | |
I-170 | |
I-208 | |
I-255 | |
I-256 | |
I-257 | |
I-188 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.